Gordon K B, Bonish B K, Patel T, Leonardi C L, Nickoloff B J
Department of Internal Medicine, Division of Dermatology, Loyola University Medical Center, Maywood, IL 60153, USA.
Br J Dermatol. 2005 Nov;153(5):945-53. doi: 10.1111/j.1365-2133.2005.06816.x.
The pathophysiology of psoriasis is poorly understood, and the mechanism of action of biological agents interfering with tumour necrosis factor (TNF)-alpha that improve psoriatic plaques is completely unknown.
To begin to unravel the mechanism of action, cellular changes occurring in plaques following administration of adalimumab, a humanized monoclonal antibody against TNF-alpha, were investigated.
Thirteen different patients underwent sequential biopsies as part of a clinical trial. Each biopsy was immunostained and evaluated to calculate the relative density of epidermal Langerhans cells (LCs) before and after treatment (days 2, 7, 28, 84). To explore the basis for reduced epidermal LC densities in plaques, a SCID-Hu animal model was utilized. Acute psoriatic lesions were created within 2 weeks by injection of superantigen-activated CD4+ T cells into engrafted symptomless skin.
Compared with symptomless skin, untreated plaques had a significantly reduced density of epidermal LCs. There was a rapid increase in density of epidermal LCs in plaques following treatment with adalimumab beginning as early as day 7. The paucity of epidermal LCs in plaques was contrasted to the prominent density of LCs in other skin disorders with chronic inflammation and alterations in keratinization, including lichen planus and inflamed seborrhoeic keratosis. Rapid creation of plaques using the SCID-Hu model was accompanied by loss of epidermal LCs, indicating that diminished LC density occurs at an early stage of lesion formation.
These data shed light on a new immunopathological perspective highlighting a rapid loss of epidermal LCs in acute psoriatic lesions, with sustained decreased density of LCs in chronic plaques. Furthermore, an unexpected insight into the mechanism of action was uncovered for adalimumab, in which rapid restoration of epidermal LC density was observed.
银屑病的病理生理学尚未完全明确,干扰肿瘤坏死因子(TNF)-α从而改善银屑病斑块的生物制剂的作用机制也完全未知。
为了开始阐明作用机制,研究了给予抗TNF-α人源化单克隆抗体阿达木单抗后斑块中发生的细胞变化。
作为一项临床试验的一部分,13名不同患者接受了序贯活检。每次活检进行免疫染色并评估,以计算治疗前及治疗后(第2天、第7天、第28天、第84天)表皮朗格汉斯细胞(LCs)的相对密度。为了探究斑块中表皮LCs密度降低的原因,使用了SCID-Hu动物模型。通过将超抗原激活的CD4+T细胞注射到移植后的无症状皮肤中,在2周内产生急性银屑病皮损。
与无症状皮肤相比,未经治疗的斑块中表皮LCs密度显著降低。使用阿达木单抗治疗后,最早在第7天,斑块中表皮LCs密度迅速增加。斑块中表皮LCs的稀少与其他伴有慢性炎症和角化改变的皮肤疾病(包括扁平苔藓和炎性脂溢性角化病)中LCs的显著密度形成对比。使用SCID-Hu模型快速形成斑块伴随着表皮LCs的丢失,表明LCs密度降低发生在病变形成的早期阶段。
这些数据揭示了一种新的免疫病理学观点,突出了急性银屑病皮损中表皮LCs的快速丢失,以及慢性斑块中LCs密度持续降低。此外,还意外地发现了阿达木单抗的作用机制,即观察到表皮LCs密度迅速恢复。